ArticleFrontiers in oncology2026
Trends in incidence and mortality of lung cancer and age-period-cohort model analysis in Zibo, Shandong Province, 2014-2024.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the leading malignancy worldwide and a major public health challenge in China. Driven by population aging, tobacco use and air pollution, its disease burden remains severe. Zibo is a densely populated industrial city with a heavy lung cancer burden. Understanding the incidence and mortality trends and quantifying age-period-cohort effects are critical for targeted prevention and control. This study analyzed data from 2014 to 2024 to identify trends and high-risk populations to inform evidence-based intervention strategies. Objective: This study aimed to examine trends in lung cancer incidence and mortality among residents of Zibo from 2014 to 2024, evaluate the independent effects of age, period and birth cohort, identify high-risk populations and thereby provide evidence for developing targeted lung cancer prevention and intervention strategies. Methods: Individual registration data on lung cancer incidence and mortality among registered residents in Zibo from 2014 to 2024 were obtained. The joinpoint regression was used to analyze temporal trends in incidence and mortality rates, and the average annual percentage change (AAPC) with 95% confidence interval ( Results: From 2014 to 2024, the age-standardized incidence rates of lung cancer among males, females and the overall population in Zibo all showed a significant upward trend, while the age-standardized mortality rates showed a downward trend. The AAPC for the overall standardized incidence rate was 4.34% (95% Conclusion: From 2014 to 2024, the incidence rate of lung cancer in Zibo continued to increase, while the mortality rate showed a downward trend. Prevention and control of lung cancer should be continuously strengthened in the elderly and males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.